Recently, the Food and Drug Administration of Taiwan’s Ministry of Health and Welfare (FDA) published a report on a new class of hypoglycemic drugs, Glucagon-like peptide-1 (GLP-1) receptor agonists. , suspected of causing acute pancreatitis.
Wang Chih-yuan, researcher and president of the Taiwan Association of Diabetes Educators, said patients who use GLP-1 receptor agonists may also experience gastrointestinal discomfort, such as nausea, vomiting, diarrhea. and other side effects. For patients with familial medullary thyroid cancer and multiple endocrine tumor syndrome, Wang strongly advised to stop using anti-diabetic drugs such as GLP-1 receptor agonists.
Wang also warns that patients who experience pancreatitis and other symptoms while taking the specific drug should seek medical attention as soon as possible.
Taiwan FDA Warning
The Taiwan FDA report points out that the number of diabetic patients has increased significantly in recent years. To date, there are 2.2 million diabetic patients. Diabetes pharmaceuticals are constantly launching new discoveries.
The latest launch of the new class of blood sugar lowering drugs consists of two new blood sugar lowering drugs, sodium-glucose-glucose collaborative transport protein-2 inhibitors (SGLT2 inhibitors) and receptor agonists.
In addition to minimizing the side effects of hypoglycemia, the drugs also contribute to cardiovascular protection and weight loss,
Therefore, some weight loss patients also use this latest hypoglycemic drug for weight loss.
However, the FDA reminded the public that the new generation of blood sugar lowering drugs recently received suspected cases of drug-induced acute pancreatitis.
He also mentioned that patients should consult a professional before taking medication and follow the doctor’s instructions for taking medication.
The Food and Drug Administration’s pharmaceutical group said there were more patients with type 2 diabetes in Taiwan, and the incidence rate for men was higher than for women. The trend shows that the age of the first incidence of diabetes has become younger.
A lifestyle change
Wang suggested improving three areas of lifestyle habits: sleep, exercise and diet. Wang said patients should go to bed at 9 or 10 p.m. with 7 to 8 hours of sleep a day.
According to previous research, taking a short nap in the afternoon for 10 to 30 minutes is a positive routine. Exercising 20-30 minutes a day can prevent physical degeneration and chronic disease.
On the other hand, a patient’s eating habits are also a vital factor in controlling blood sugar levels. Wang said controlling human nutrition is now different from the past.
Modern nutritional monitoring no longer uses outdated standards to count the number of bowls of rice or vegetables to eat. Instead, it focuses on what kind of foods you like to eat and how often you eat them.
“Patients can now achieve a healthy lifestyle goal by balancing the amount of food intake to control blood sugar.”
The FDA has warned the public that all drugs carry risks and that patients should only obtain drugs through legal channels. Medicines should not be purchased privately or used without a doctor’s prescription.
The FDA also mentioned that SGLT 2 inhibitors and GLP-1 receptor agonists are prescription-only drugs. Patients should consult medical professionals about the risks and benefits of drug use.
The latest advice on how best to ensure safe drug use from the FDA: Patients should proactively inform their physician of current medical prescription, medical history, and drug allergy and Consume medicine on time as per doctor’s instructions.